"2025 Sun Life Hong Kong International Dragon Boat Races" Successfully Concluded in Acclamation
Cancer patients, survivors and their loves ones formed an inaugural dragon boat team Citizens and tourists dive into the Dragon Boat Frenzy
HONG KONG SAR - Media OutReach Newswire - 9 June 2025 - The '2025 Sun Life Hong Kong International Dragon Boat Races', organized by the Hong Kong Tourism Board in collaboration with the Hong Kong China Dragon Boat Association and proudly title-sponsored by Sun Life, saw the city's waterfront come alive over the weekend as a huge crowd came to enjoy the mix of international competition and cultural tradition, along with a range of other fun activities.
Sun Life has 21 teams composed of advisors, employees and partners participate in the 'Sun Life Elite Cup', actively supporting the city's dragon boat racing culture.
The annual event attracted numerous citizens to the East Tsim Sha Tsui promenade over the two days (June 7-8) to witness 19 thrilling races in Victoria Harbour that drew over 190 teams and more than 4,500 paddlers from around the world. Among the races, the new 'Sun Life Elite Cup' saw enthusiastic participation from 21 teams made up of Sun Life's advisors, employees, and partners, underscoring the company's commitment to preserving and promoting dragon boat culture.
Demonstrating its strong commitment to the community, Sun Life has proudly sponsored Maggie's Cancer Caring Centre to form the 'Move for Maggie's Dragon Boat Team'. Comprised of cancer patients, survivors, and their loved ones, the team made an impactful debut at this year's 'Sun Life Elite Cup', raising funds to support individuals affected by cancer. Dr. the Hon Leong Che-Hung, GBM, GBS, OBE, JP, Chairman of the Board of Governors at Maggie's Cancer Caring Centre, attended the event to cheer on the inspiring paddlers. Proceeds from the fundraising will enhance the Centre's free support services, while the dragon boat race itself delivers a powerful message of hope and resilience. Through this initiative, participants and supporters alike embrace a positive outlook on living with cancer, inspiring patients and their families to face challenges with renewed courage and hope.
Mr. Clement Lam, Chief Executive Officer of Sun Life Hong Kong Limited, said: 'As an international financial institution rooted in Hong Kong for over 130 years, our 16-year commitment to local dragon boat racing reflects not only our dedication to sustaining cultural heritage, but also our pledge to grow alongside this city. We are proud that Sun Life has helped propel this tradition onto the global stage, embodying the city's spirit of teamwork and energy. Moving forward, we will continue to support diverse sports initiatives, offering innovative experiences that blend athletics, culture, and entertainment for citizens and tourists, ultimately helping our Clients live healthier lives while also creating societal value.'
Alongside the main event, Sun Life launched a variety of engaging promotional activities, both online and offline, that attracted widespread participation across the city. A highlight was the 'Sun Life Dragon Boat House', a giant interactive installation at K11 MUSEA that became a viral sensation. Through its multi-platform campaign, Sun Life helped deepen public appreciation for this cultural tradition – and encouraged greater participation too.
The triumph of the '2025 Sun Life Hong Kong International Dragon Boat Races' reflects the ability of Hong Kong to host world-class events and attract new audiences to an old tradition. It all bodes well for next year.
Hashtag: #SunLife永明 #永明金融 #SunLife #香港國際龍舟邀請賽 #龍舟 #盛事 #盛事之都 #旅發局 #銘琪癌症關顧中心 #HongKongInternationalDragonBoatRaces #dragonboat #megaevent #eventscapital #tourismboard #Maggie'sCanceCaringCentre
The issuer is solely responsible for the content of this announcement.
About Sun Life
Sun Life is a leading international financial services organization providing asset management, wealth, insurance and health solutions to individual and institutional Clients. Sun Life has operations in a number of markets worldwide, including Canada, the United States, the United Kingdom, Ireland, Hong Kong, the Philippines, Japan, Indonesia, India, China, Australia, Singapore, Vietnam, Malaysia and Bermuda. As of March 31, 2025, Sun Life had total assets under management of $1.55 trillion. For more information, please visit www.sunlife.com.
Sun Life Financial Inc. trades on the Toronto (TSX), New York (NYSE) and Philippine (PSE) stock exchanges under the ticker symbol SLF. Sun Life Financial Inc. is the holding company of Sun Life Assurance Company of Canada. Sun Life Hong Kong Limited is a wholly-owned subsidiary of Sun Life Assurance Company of Canada.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
3 Asian Penny Stocks With Market Caps Larger Than US$100M
Amidst ongoing trade tensions and fluctuating economic indicators, Asian markets have been a focal point of global investor attention. Penny stocks, often seen as smaller or newer companies with lower price points, continue to offer intriguing opportunities for growth. Despite their vintage-sounding name, these stocks can still present significant value when backed by strong financials and fundamentals. Name Share Price Market Cap Financial Health Rating YKGI (Catalist:YK9) SGD0.10 SGD42.5M ★★★★★★ Lever Style (SEHK:1346) HK$1.16 HK$731.9M ★★★★★★ TK Group (Holdings) (SEHK:2283) HK$2.06 HK$1.72B ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.43 SGD174.27M ★★★★★☆ Goodbaby International Holdings (SEHK:1086) HK$1.23 HK$2.05B ★★★★★★ Halcyon Technology (SET:HTECH) THB2.64 THB792M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.31 SGD9.09B ★★★★★☆ Beng Kuang Marine (SGX:BEZ) SGD0.184 SGD36.66M ★★★★★★ BRC Asia (SGX:BEC) SGD3.14 SGD861.46M ★★★★★★ Bosideng International Holdings (SEHK:3998) HK$4.56 HK$52.24B ★★★★★★ Click here to see the full list of 1,148 stocks from our Asian Penny Stocks screener. Underneath we present a selection of stocks filtered out by our screen. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Shanghai Bio-heart Biological Technology Co., Ltd. (SEHK:2185) is a company focused on developing and commercializing innovative medical devices for cardiovascular diseases, with a market cap of HK$905.51 million. Operations: Shanghai Bio-heart Biological Technology Co., Ltd. does not report specific revenue segments. Market Cap: HK$905.51M Shanghai Bio-heart Biological Technology, with a market cap of HK$905.51 million, remains pre-revenue while focusing on innovative medical devices for cardiovascular diseases. The company has effectively managed its liabilities, with short-term assets significantly exceeding both short and long-term liabilities. Despite being unprofitable, it has reduced losses by 20.7% annually over five years and maintains a debt-free status. Recent developments include the successful enrollment in a Japanese trial for its sirolimus drug-coated balloon product, which may offer advantages over existing treatments due to its anti-inflammatory properties and prolonged drug release capabilities. However, high share price volatility persists amidst these advancements. Dive into the specifics of Shanghai Bio-heart Biological Technology here with our thorough balance sheet health report. Gain insights into Shanghai Bio-heart Biological Technology's historical outcomes by reviewing our past performance report. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Tian An China Investments Company Limited is an investment holding company that focuses on investing in, developing, and managing properties in the People's Republic of China, Hong Kong, and the United Kingdom with a market cap of HK$6.52 billion. Operations: The company's revenue is primarily derived from its healthcare segment, which generated HK$1.58 billion, followed by property investment at HK$583.52 million and property development at HK$520.46 million, with additional income from other operations amounting to HK$327.21 million. Market Cap: HK$6.52B Tian An China Investments is navigating financial challenges, reporting a net loss of HK$207.08 million for 2024, down from a profit the previous year. Despite seasoned management and strong asset coverage over liabilities, the company faces hurdles with declining revenues in property sales due to market downturns and lack of new project handovers. Its debt is well-managed with cash flow covering interest payments effectively, yet it remains unprofitable with increasing losses over five years. The recent dividend decrease reflects these financial strains as the company trades significantly below its estimated fair value amidst industry volatility. Click here to discover the nuances of Tian An China Investments with our detailed analytical financial health report. Evaluate Tian An China Investments' historical performance by accessing our past performance report. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Digital China Holdings Limited is an investment holding company that offers big data products and solutions to government and enterprise customers in Mainland China, with a market cap of HK$5.56 billion. Operations: The company's revenue is primarily derived from three segments: CN¥3.24 billion from big data products and solutions, CN¥5.52 billion from software and operating services, and CN¥7.96 billion from traditional and localization services. Market Cap: HK$5.56B Digital China Holdings is grappling with financial challenges, posting a net loss of CN¥253.95 million for 2024, though this marks an improvement from the previous year's larger deficit. The company's short-term assets comfortably cover both its short and long-term liabilities, and it maintains a solid cash position relative to debt. Despite these strengths, profitability remains elusive due to ongoing losses in associates and impairments on investments. Management's tenure is experienced; however, the board's limited experience could pose governance challenges. A proposed dividend suggests some confidence in future prospects despite current unprofitability. Click here and access our complete financial health analysis report to understand the dynamics of Digital China Holdings. Explore historical data to track Digital China Holdings' performance over time in our past results report. Take a closer look at our Asian Penny Stocks list of 1,148 companies by clicking here. Interested In Other Possibilities? Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:2185 SEHK:28 and SEHK:861. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
a day ago
- Bloomberg
Why China Biotech Is Getting a DeepSeek Moment, Too
From artificial intelligence to military defense, China has offered a few DeepSeek moments this year, showcasing that the country is more than just the world's biggest factory, and that it also can compete with the US on the technology front. Now biotech is having its own. In late May, Pfizer Inc. agreed to pay a record $1.25 billion upfront to license an experimental cancer drug from Shenyang-based 3SBio Inc., as well as making a $100 million equity investment in the Hong Kong-listed biotech company. Two weeks later, Bristol-Myers Squibb Co. said it would pay BioNTech SE $1.5 billion guaranteed to license a similar cancer asset. It was a win for BioNTech, which bought Biotheus Inc., the Chinese company that developed the drug, late last year for $800 million.
Wall Street Journal
a day ago
- Wall Street Journal
Colonoscopies Beat the Alternative Every Day
I read Jim Sollisch's complaints about the discomfort of colonoscopy preparation with amusement and concern ('Colonoscopy Prep Is Worse Than IKEA,' op-ed, June 3). I have had 12 colonoscopies since I was 50 thanks to a family history of colon cancer. The prep is uncomfortable and inconvenient. The alternative is far worse. My father was diagnosed with this terrible cancer in 1958. Doctors gave him six months to live in a time before colostomies were common. He lasted five years—a time I cherish—but the cost to him was high. I think watching someone die from colon cancer might help Mr. Sollisch put the prep into perspective. It isn't as unbearable as he describes, and I would never want to see anyone decline a procedure for one of the most preventable cancers. If you are at risk for colon cancer, schedule your procedure today. Ken Gurak
